It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Clonal hematopoiesis (CH)—age-related expansion of mutated hematopoietic clones—can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our analysis suggests a cellular evolutionary trade-off between different types of CH, with LOY occurring at lower rates in individuals carrying mutations in established CHIP genes. We observed co-occurrence of CHIP and mCAs with overlap at TET2, DNMT3A, and JAK2, in which CHIP precedes mCA acquisition. Furthermore, individuals carrying overlapping CH had high risk of future lymphoid and myeloid malignancies. Finally, we leverage shared genetic architecture of CH traits to identify 15 novel loci associated with leukemia risk.
Types of clonal hematopoiesis (CH) differ in frequency and fitness. These findings uncover shared genetic architecture, suggest evolutionary trade-offs between CH types, and detail elevated leukemia risk in individuals with overlapping types of CH.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075); National Cancer Institute, Cancer Prevention Fellowship Program, Division of Cancer Prevention, Rockville, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
2 Dana-Farber Cancer Institute, Harvard Medical School, Division of Hematology/Oncology, Boston Children’s Hospital and Department of Pediatric Oncology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34)
3 University of Cambridge School of Clinical Medicine, MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
4 Dana-Farber Cancer Institute, Harvard Medical School, Division of Hematology/Oncology, Boston Children’s Hospital and Department of Pediatric Oncology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Albert Einstein Cancer Center, Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, USA (GRID:grid.516102.1) (ISNI:0000 0004 1799 294X)
5 National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
6 University of Cambridge School of Clinical Medicine, MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge School of Clinical Medicine, Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)